So MannKind just brought in Dominic Marasco as the new head of their endocrine business unit. Guy's got like 25+ years in biopharma, worked at Amgen, BioAgilytix, Envision Pharma – pretty solid resume for someone stepping into this role. Started back in January last year if I remember right.



The move seems pretty strategic honestly. They're betting on Afrezza gaining traction, and bringing in someone like Marasco with that kind of commercial background makes sense. He's supposed to help scale things up, especially with their inhaled delivery tech for diabetes and lung diseases.

That said, the insider trading activity is kinda interesting – been seeing mostly sells from their executives over the past few quarters. Marasco's got his work cut out for him. Worth watching how this plays out for $MNKD.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin